Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation
Abstract Objective To report our clinical experience using continuous intrathecal baclofen (ITB) trials prior to permanent pump implantation. Design Retrospective chart review. Setting An inpatient neurosurgery unit and outpatient physical medicine and rehabilitation clinics. Participants Fifty-seve...
Gespeichert in:
Veröffentlicht in: | PM & R 2015-10, Vol.7 (10), p.1052-1058 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1058 |
---|---|
container_issue | 10 |
container_start_page | 1052 |
container_title | PM & R |
container_volume | 7 |
creator | Phillips, Mary Miller, MD Miljkovic, Natasa, MD, PhD Ramos-Lamboy, Marlyn, MD Moossy, John J., MD Horton, John, MD Buhari, Alhaji M., MA, MSIE Munin, Michael C., MD |
description | Abstract Objective To report our clinical experience using continuous intrathecal baclofen (ITB) trials prior to permanent pump implantation. Design Retrospective chart review. Setting An inpatient neurosurgery unit and outpatient physical medicine and rehabilitation clinics. Participants Fifty-seven patients with refractory spasticity who underwent a continuous ITB trial during the years 2006-2012. Methods Patients underwent placement of a temporary intrathecal catheter that was connected to an external pump. A successful trial was defined as a one-level reduction in lower limb modified Ashworth scores in key spastic lower limb muscles identified for each individual patient. Subjective improvement in function or ease of performing functional tasks also were monitored. Main Outcome Measures Modified Ashworth scores, functional mobility in ambulatory patients only, and the incidence and severity of adverse events during the trial and up to 1 year after implantation. Results Spasticity significantly decreased during the trial. Average ambulation distance was unchanged, although 34% of ambulatory patients progressed to a less restrictive assistive device by trial completion. Adverse events (AEs) occurred in 26 patients. Minor AEs were seen in 18 patients, with the most common being nausea, transient urinary retention, and headache. Pumps were implanted in 86% of patients; 14% did not receive a pump because of AEs or because goals were not met. Six patients had their pump removed at 12 months for the following reasons: pump malfunctions (3), skin breakdown around the pump (1), infection (1), and expectations not met (1). Conclusions Continuous trials via an external catheter could be an option if patients and clinicians desire a comprehensive assessment of systemic and functional effects of ITB before pump implantation. The majority of AEs were minor and resolved spontaneously, and the most effective starting intrathecal dose was determined by pump insertion. |
doi_str_mv | 10.1016/j.pmrj.2015.03.020 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1727435825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1934148215001720</els_id><sourcerecordid>1727435825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4932-78c907e0db544be4daa6ebf316ec7b8eadf4f20ce954807fbaa0a22f959b788c3</originalsourceid><addsrcrecordid>eNqNkk9v1DAQxS1ERUvhC3BAOXLZMP6TxJEQEl2VsqgVKyhC4mI5zkR1SOJgJ7T77XHYLYceECfP4b2n598MIS8opBRo_rpNx963KQOapcBTYPCInNCSixXNcv74fhaSHZOnIbQAuaAyf0KOWSaZZCBOyPd1ZwdrdJec343oLQ4Gk292uknWbpjsMLs5JJth8nq6wUV2pk3nGhySa291F5Ktt84nk0u2cz8mm37s9DDpybrhGTlqogKfH95T8vX9-fX6w-ry08Vm_e5yZUTJ2aqQpoQCoa4yISoUtdY5Vg2nOZqikqjrRjQMDJaZkFA0ldagGWvKrKwKKQ0_Ja_2uaN3P2cMk-ptMNjFIhjbK1qwQvD44yxK2V5qvAvBY6NGb3vtd4qCWpiqVi1M1cJUAVeRaTS9POTPVY_1X8s9xCiQe8Gt7XD3H5Fqe_X5I4WMReubvRUjoF8WvQrmzw5q69FMqnb239XePrCbwzp_4A5D62Y_RPSKqsAUqC_LQSz3QDOAiAX4b0gdr7g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1727435825</pqid></control><display><type>article</type><title>Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Phillips, Mary Miller, MD ; Miljkovic, Natasa, MD, PhD ; Ramos-Lamboy, Marlyn, MD ; Moossy, John J., MD ; Horton, John, MD ; Buhari, Alhaji M., MA, MSIE ; Munin, Michael C., MD</creator><creatorcontrib>Phillips, Mary Miller, MD ; Miljkovic, Natasa, MD, PhD ; Ramos-Lamboy, Marlyn, MD ; Moossy, John J., MD ; Horton, John, MD ; Buhari, Alhaji M., MA, MSIE ; Munin, Michael C., MD</creatorcontrib><description>Abstract Objective To report our clinical experience using continuous intrathecal baclofen (ITB) trials prior to permanent pump implantation. Design Retrospective chart review. Setting An inpatient neurosurgery unit and outpatient physical medicine and rehabilitation clinics. Participants Fifty-seven patients with refractory spasticity who underwent a continuous ITB trial during the years 2006-2012. Methods Patients underwent placement of a temporary intrathecal catheter that was connected to an external pump. A successful trial was defined as a one-level reduction in lower limb modified Ashworth scores in key spastic lower limb muscles identified for each individual patient. Subjective improvement in function or ease of performing functional tasks also were monitored. Main Outcome Measures Modified Ashworth scores, functional mobility in ambulatory patients only, and the incidence and severity of adverse events during the trial and up to 1 year after implantation. Results Spasticity significantly decreased during the trial. Average ambulation distance was unchanged, although 34% of ambulatory patients progressed to a less restrictive assistive device by trial completion. Adverse events (AEs) occurred in 26 patients. Minor AEs were seen in 18 patients, with the most common being nausea, transient urinary retention, and headache. Pumps were implanted in 86% of patients; 14% did not receive a pump because of AEs or because goals were not met. Six patients had their pump removed at 12 months for the following reasons: pump malfunctions (3), skin breakdown around the pump (1), infection (1), and expectations not met (1). Conclusions Continuous trials via an external catheter could be an option if patients and clinicians desire a comprehensive assessment of systemic and functional effects of ITB before pump implantation. The majority of AEs were minor and resolved spontaneously, and the most effective starting intrathecal dose was determined by pump insertion.</description><identifier>ISSN: 1934-1482</identifier><identifier>EISSN: 1934-1563</identifier><identifier>DOI: 10.1016/j.pmrj.2015.03.020</identifier><identifier>PMID: 25828204</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Baclofen - administration & dosage ; Dose-Response Relationship, Drug ; Female ; Humans ; Infusion Pumps, Implantable ; Injections, Spinal ; Male ; Middle Aged ; Muscle Relaxants, Central - administration & dosage ; Muscle Spasticity - drug therapy ; Muscle Spasticity - etiology ; Physical Medicine and Rehabilitation ; Retrospective Studies ; Treatment Outcome</subject><ispartof>PM & R, 2015-10, Vol.7 (10), p.1052-1058</ispartof><rights>American Academy of Physical Medicine and Rehabilitation</rights><rights>2015 American Academy of Physical Medicine and Rehabilitation</rights><rights>2015 by the American Academy of Physical Medicine and Rehabilitation</rights><rights>Copyright © 2015 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4932-78c907e0db544be4daa6ebf316ec7b8eadf4f20ce954807fbaa0a22f959b788c3</citedby><cites>FETCH-LOGICAL-c4932-78c907e0db544be4daa6ebf316ec7b8eadf4f20ce954807fbaa0a22f959b788c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1016%2Fj.pmrj.2015.03.020$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1016%2Fj.pmrj.2015.03.020$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25828204$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Phillips, Mary Miller, MD</creatorcontrib><creatorcontrib>Miljkovic, Natasa, MD, PhD</creatorcontrib><creatorcontrib>Ramos-Lamboy, Marlyn, MD</creatorcontrib><creatorcontrib>Moossy, John J., MD</creatorcontrib><creatorcontrib>Horton, John, MD</creatorcontrib><creatorcontrib>Buhari, Alhaji M., MA, MSIE</creatorcontrib><creatorcontrib>Munin, Michael C., MD</creatorcontrib><title>Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation</title><title>PM & R</title><addtitle>PM R</addtitle><description>Abstract Objective To report our clinical experience using continuous intrathecal baclofen (ITB) trials prior to permanent pump implantation. Design Retrospective chart review. Setting An inpatient neurosurgery unit and outpatient physical medicine and rehabilitation clinics. Participants Fifty-seven patients with refractory spasticity who underwent a continuous ITB trial during the years 2006-2012. Methods Patients underwent placement of a temporary intrathecal catheter that was connected to an external pump. A successful trial was defined as a one-level reduction in lower limb modified Ashworth scores in key spastic lower limb muscles identified for each individual patient. Subjective improvement in function or ease of performing functional tasks also were monitored. Main Outcome Measures Modified Ashworth scores, functional mobility in ambulatory patients only, and the incidence and severity of adverse events during the trial and up to 1 year after implantation. Results Spasticity significantly decreased during the trial. Average ambulation distance was unchanged, although 34% of ambulatory patients progressed to a less restrictive assistive device by trial completion. Adverse events (AEs) occurred in 26 patients. Minor AEs were seen in 18 patients, with the most common being nausea, transient urinary retention, and headache. Pumps were implanted in 86% of patients; 14% did not receive a pump because of AEs or because goals were not met. Six patients had their pump removed at 12 months for the following reasons: pump malfunctions (3), skin breakdown around the pump (1), infection (1), and expectations not met (1). Conclusions Continuous trials via an external catheter could be an option if patients and clinicians desire a comprehensive assessment of systemic and functional effects of ITB before pump implantation. The majority of AEs were minor and resolved spontaneously, and the most effective starting intrathecal dose was determined by pump insertion.</description><subject>Adult</subject><subject>Baclofen - administration & dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Infusion Pumps, Implantable</subject><subject>Injections, Spinal</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscle Relaxants, Central - administration & dosage</subject><subject>Muscle Spasticity - drug therapy</subject><subject>Muscle Spasticity - etiology</subject><subject>Physical Medicine and Rehabilitation</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1934-1482</issn><issn>1934-1563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk9v1DAQxS1ERUvhC3BAOXLZMP6TxJEQEl2VsqgVKyhC4mI5zkR1SOJgJ7T77XHYLYceECfP4b2n598MIS8opBRo_rpNx963KQOapcBTYPCInNCSixXNcv74fhaSHZOnIbQAuaAyf0KOWSaZZCBOyPd1ZwdrdJec343oLQ4Gk292uknWbpjsMLs5JJth8nq6wUV2pk3nGhySa291F5Ktt84nk0u2cz8mm37s9DDpybrhGTlqogKfH95T8vX9-fX6w-ry08Vm_e5yZUTJ2aqQpoQCoa4yISoUtdY5Vg2nOZqikqjrRjQMDJaZkFA0ldagGWvKrKwKKQ0_Ja_2uaN3P2cMk-ptMNjFIhjbK1qwQvD44yxK2V5qvAvBY6NGb3vtd4qCWpiqVi1M1cJUAVeRaTS9POTPVY_1X8s9xCiQe8Gt7XD3H5Fqe_X5I4WMReubvRUjoF8WvQrmzw5q69FMqnb239XePrCbwzp_4A5D62Y_RPSKqsAUqC_LQSz3QDOAiAX4b0gdr7g</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Phillips, Mary Miller, MD</creator><creator>Miljkovic, Natasa, MD, PhD</creator><creator>Ramos-Lamboy, Marlyn, MD</creator><creator>Moossy, John J., MD</creator><creator>Horton, John, MD</creator><creator>Buhari, Alhaji M., MA, MSIE</creator><creator>Munin, Michael C., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation</title><author>Phillips, Mary Miller, MD ; Miljkovic, Natasa, MD, PhD ; Ramos-Lamboy, Marlyn, MD ; Moossy, John J., MD ; Horton, John, MD ; Buhari, Alhaji M., MA, MSIE ; Munin, Michael C., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4932-78c907e0db544be4daa6ebf316ec7b8eadf4f20ce954807fbaa0a22f959b788c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Baclofen - administration & dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Infusion Pumps, Implantable</topic><topic>Injections, Spinal</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscle Relaxants, Central - administration & dosage</topic><topic>Muscle Spasticity - drug therapy</topic><topic>Muscle Spasticity - etiology</topic><topic>Physical Medicine and Rehabilitation</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Phillips, Mary Miller, MD</creatorcontrib><creatorcontrib>Miljkovic, Natasa, MD, PhD</creatorcontrib><creatorcontrib>Ramos-Lamboy, Marlyn, MD</creatorcontrib><creatorcontrib>Moossy, John J., MD</creatorcontrib><creatorcontrib>Horton, John, MD</creatorcontrib><creatorcontrib>Buhari, Alhaji M., MA, MSIE</creatorcontrib><creatorcontrib>Munin, Michael C., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>PM & R</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Phillips, Mary Miller, MD</au><au>Miljkovic, Natasa, MD, PhD</au><au>Ramos-Lamboy, Marlyn, MD</au><au>Moossy, John J., MD</au><au>Horton, John, MD</au><au>Buhari, Alhaji M., MA, MSIE</au><au>Munin, Michael C., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation</atitle><jtitle>PM & R</jtitle><addtitle>PM R</addtitle><date>2015-10</date><risdate>2015</risdate><volume>7</volume><issue>10</issue><spage>1052</spage><epage>1058</epage><pages>1052-1058</pages><issn>1934-1482</issn><eissn>1934-1563</eissn><abstract>Abstract Objective To report our clinical experience using continuous intrathecal baclofen (ITB) trials prior to permanent pump implantation. Design Retrospective chart review. Setting An inpatient neurosurgery unit and outpatient physical medicine and rehabilitation clinics. Participants Fifty-seven patients with refractory spasticity who underwent a continuous ITB trial during the years 2006-2012. Methods Patients underwent placement of a temporary intrathecal catheter that was connected to an external pump. A successful trial was defined as a one-level reduction in lower limb modified Ashworth scores in key spastic lower limb muscles identified for each individual patient. Subjective improvement in function or ease of performing functional tasks also were monitored. Main Outcome Measures Modified Ashworth scores, functional mobility in ambulatory patients only, and the incidence and severity of adverse events during the trial and up to 1 year after implantation. Results Spasticity significantly decreased during the trial. Average ambulation distance was unchanged, although 34% of ambulatory patients progressed to a less restrictive assistive device by trial completion. Adverse events (AEs) occurred in 26 patients. Minor AEs were seen in 18 patients, with the most common being nausea, transient urinary retention, and headache. Pumps were implanted in 86% of patients; 14% did not receive a pump because of AEs or because goals were not met. Six patients had their pump removed at 12 months for the following reasons: pump malfunctions (3), skin breakdown around the pump (1), infection (1), and expectations not met (1). Conclusions Continuous trials via an external catheter could be an option if patients and clinicians desire a comprehensive assessment of systemic and functional effects of ITB before pump implantation. The majority of AEs were minor and resolved spontaneously, and the most effective starting intrathecal dose was determined by pump insertion.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25828204</pmid><doi>10.1016/j.pmrj.2015.03.020</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1934-1482 |
ispartof | PM & R, 2015-10, Vol.7 (10), p.1052-1058 |
issn | 1934-1482 1934-1563 |
language | eng |
recordid | cdi_proquest_miscellaneous_1727435825 |
source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
subjects | Adult Baclofen - administration & dosage Dose-Response Relationship, Drug Female Humans Infusion Pumps, Implantable Injections, Spinal Male Middle Aged Muscle Relaxants, Central - administration & dosage Muscle Spasticity - drug therapy Muscle Spasticity - etiology Physical Medicine and Rehabilitation Retrospective Studies Treatment Outcome |
title | Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T09%3A55%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Experience%20With%20Continuous%20Intrathecal%20Baclofen%20Trials%20Prior%20to%20Pump%20Implantation&rft.jtitle=PM%20&%20R&rft.au=Phillips,%20Mary%20Miller,%20MD&rft.date=2015-10&rft.volume=7&rft.issue=10&rft.spage=1052&rft.epage=1058&rft.pages=1052-1058&rft.issn=1934-1482&rft.eissn=1934-1563&rft_id=info:doi/10.1016/j.pmrj.2015.03.020&rft_dat=%3Cproquest_cross%3E1727435825%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1727435825&rft_id=info:pmid/25828204&rft_els_id=1_s2_0_S1934148215001720&rfr_iscdi=true |